Xadion

Reversal of rocuronium- or vecuronium-induced neuromuscular blockade in patients ≥2 yr.

IV bolus Adult Routine reversal Recommended dose: 4 mg/kg as single inj if recovery has reached at least 1-2 post-tetanic counts or 2 mg/kg as single inj if spontaneous recovery has occurred up to reappearance of T₂ following rocuronium- or vecuronium-induced blockade. Immediate reversal of rocuronium-induced blockade 16 mg/kg as single inj 3 min after bolus dose of rocuronium Br 1.2 mg/kg. Recurrence of neuromuscular blockade post-op Repeat dose of 4 mg/kg after initial dose of 2 or 4 mg/kg. Childn & adolescent ≥2 yr Routine reversal Recommended dose: 4 mg/kg as single inj if recovery has reached at least 1-2 post-tetanic counts or 2 mg/kg as single inj at reappearance of T₂ following rocuronium- or vecuronium-induced blockade.

Hypersensitivity.

Hypersensitivity including anaphylactic reactions. Not to be used to reverse block induced by nonsteroidal neuromuscular blocking agents eg, succinylcholine or benzylisoquinolinium compds; for reversal of neuromuscular blockade induced by steroidal neuromuscular blockers other than rocuronium or vecuronium; reversal of pancuronium-induced blockade. Recurrence of neuromuscular blockade; signs of light anaesth; marked bradycardia. Delayed recovery time in CV disease, edematous state. Monitor resp function during recovery; coagulation parameters in patients w/ known coagulopathies & using anticoagulants; hemodynamic changes during & after neuromuscular blockade reversal. Patients receiving rocuronium or vecuronium in ICU setting; on controlled Na diet. Concomitant use w/ medicinal products potentiating neuromuscular blockade in post-op; hormonal contraceptives; toremifene, fusidic acid. Not recommended in severe renal impairment including patients requiring dialysis (CrCl <30 mL/min). Severe hepatic impairment; hepatic impairment accompanied by coagulopathy. Pregnancy & lactation. Not recommended in term newborn infants & infants. Not recommended in immediate reversal in childn & adolescents. Delayed recovery time in elderly.

Cough; airway anaesth complication, anaesth complication, procedural hypotension & complication.

Complex displacement of vecuronium or rocuronium w/ toremifene. Delayed recovery in pre-op phase w/ IV fusidic acid. Decreased progestogen exposure. Reduced effectiveness of OCs. Interference w/ serum progesterone assay.

Antidotes & Detoxifying Agents

V03AB35 - sugammadex ; Belongs to the class of antidotes. Used to reverse neuromuscular blockade caused by rocuronium or vecuronium.

B